IDRI is a nonprofit biotech organization taking a comprehensive approach to develop new solutions for infectious disease. We combine the high-quality science of a research or academic organization with the product development capabilities of a life science company, including an onsite GMP manufacturing facility.
IDRI conducts pioneering research on the biology, immunology, treatment and prevention of disease with an enviable record of peer-reviewed federal and foundation funding.
IDRI scientists are world-experts in process and product development. Our formulations team has innovated the methods to inexpensively produce, at scale, global health solutions that can be locally made and survive the toughest of shipping, storage, and health system conditions.
IDRI is committed to sharing our technology worldwide and to provide access to those who need it most. IDRI adjuvants are made on five continents, locally owned by partners in India, South Africa, Brazil, Korea and Europe.
Our goal is to create vaccine platforms and technologies to combat the worlds most devastating infectious diseases.
Deep basic and translational research
Early-phase or partnered clinical research
Discovery and Innovation
Limited ability to manufacture or scale
Developing products for market
Discovery and Innovation
Ability to manufacture specialty products at scale
We are a leader in manufacturing and development of vaccines and adjuvants for research and early clinical trials
RNA vaccine technologies can be quickly adapted to target new and emerging pathogens when epidemics hit, and readily manufactured in pre-optimized processes. IDRI has a promising vaccine platform that uses a replicating RNA molecule to express viral antigens, formulated and delivered to injection sites with a nanostructured lipid carrier system that can be stockpiled for use in future epidemic situations.
Adjuvants are an important part of an outbreak response, dramatically increasing vaccine availability. Adjuvants provide three key benefits to vaccine development:
IDRI is working to eliminate death by the most common cancers that affect women and children, by developing and advancing lower cost, more effective and readily available immunotherapies. Our immune-stimulating adjuvants and formulations are also currently in active trials with vaccines to combat HIV, TB, leprosy and other neglected diseases. Our focus is on innovation and manufacture of vaccine platforms and therapies to aid in pandemic response and reduce the burden of infectious disease and cancers around the globe
IDRI performs formulation development, fill & finish services, and ICH compliant stability studies in its state-of-the-art labs and cGMP facilities. Our formulation development services focus on liquid, emulsion and liposome formulations.
We specialize in manufacturing large and small molecules in liquid formulations, vaccines and adjuvants in liquid forms, emulsions and liposomes. Customization of complex adjuvant formulations based on emulsions and liposomes have long been part of IDRI’s core expertise.
IDRI provides analytical development and quality control services to support formulation development, manufacturing, product release and stability studies. New methods may be developed and qualified, and existing compendia methods verified as needed.
We work with clients to execute their protocol, design a protocol, or mutually design the right stability study to accommodate any special needs associated with a client’s drug product. The protocol specifies frequency of testing and storage conditions (temperatures, position); appropriate stability-indicating methods; and degradation products that may be stability limiting.
We respect compassion, scientific excellence, innovation and teamwork. Our staff of scientists and professionals is looking for qualified individuals to join our team.